Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals
Status:
Completed
Trial end date:
1991-04-01
Target enrollment:
Participant gender:
Summary
To determine the safety and effectiveness of dextran sulfate when it is administered
intravenously at the maximum tolerated dose (MTD) as a treatment for HIV infection in AIDS
patients. The effect of dextran sulfate on platelet survival will also be assessed in 3
patients to help determine the mechanism of thrombocytopenia (low platelets) noted in all
patients receiving intravenous dextran sulfate in this study.
Dextran sulfate appears to inhibit HIV in experiments in the test tube, but studies conducted
in humans to determine its effect on HIV when dextran sulfate is given orally have not been
conclusive. It is hoped that this study will show that dextran sulfate administered
intravenously
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)